Len Brandt

Chairman of the Board

As a member of Applied Biology’s Board of Directors, Mr. Brandt is integral to the Company’s strategic business objectives. Educated at Harvard, Len brings an extensive background in healthcare-related investment funds and experience from the venture capital field to Applied Biology.

As General Partner at Norwest Ventures, Mr. Brandt led the fund’s investment activity for ten years in all areas of healthcare. He was Partner and Co-founder of Embro Vascular, the dominant device technology for least invasive harvesting of saphenous veins for heart bypass surgery marketed by Boston Scientific, Guidant, and Macquet. Along side the founders of Home Diagnostics, Inc., the team successfully engineered a company turn-around that led to its sale to Nipro, Inc and a return to founders of almost $100MM. Additionally, Mr. Brandt was Founder and CEO of CNS Response, a big data translational database guiding medication selection in psychiatry. At CNS he defined the vision and core offering, was primary inventor on several patents leveraging off of the initial application, and organized all financings including reverse merge into public company with associated PIPE financing. Currently, he is involved with several young ventures seeking to “do well by doing good”.

Prof. Andy Goren, MD

Board Member

Prof. Andy Goren has over 20 years of experience in research, development and commercialization of breakthrough therapeutics and diagnostics.

Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia.

Prof. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy induced alopecia, excessive hair shedding, and female sexual dysfunction. His latest research involves the development of dermatology therapies based on genetically modified organisms.

Prof. Goren currently serves as a visiting Professor at the Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice in Zagreb, Croatia; a visiting Medical Doctor at the Department of Dermatology and Venereology, L.T.M. Medical College Sion in Mumbai, India; a Medical Doctor at the Skin & Cosmetic Research Dept. Shanghai Skin Disease Hospital, Shanghai, China; and the Global Medical Director of Hairmore Group in Beijing, China.

Prof. Goren has published dozens of manuscripts in dermatology. He is an honorary as well as ordinary member of several dermatology societies world-wide as well as a regular lecturer at dermatology congresses around the world. He held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers.

Scott Olson, Esq.

Board Member

Scott Olson is a business and technology focused attorney with a practice concentration in general counsel and management services. Scott has expertise in commercial transactions, equity and debt financings, mergers and acquisitions, employment and services contracts and counseling, litigation management, settlement negotiations, entertainment transactions, environmental compliance, federal investigations, aviation law, government contracting, corporate governance, business counseling, licensing, public company reporting, and other general corporate representation.

Scott has represented a wide variety of companies ranging from private start-ups to mature public companies in various industries including genetics, aviation, creative agencies, software and technology, renewable energy and apparel.